Fresh arterial homografts are immunogenic, inducing in recipient a strong immune response specifically directed against the antigens of the donor graft. The initial immune response seems to be cellular (lymphocytotoxic) and the late reaction humoral (antibody), even if they are stricty correlated. Immunosuppressive therapy reduce the immune reaction, but this response is dose-related. Implanted arterial homografts induce a donor-specific response similar to chronic reaction, which occurs in the recipients of vascularized solid-organ allografts. Therefore, in arterial transplantation, ABO compatibility and negative crossmatch should be respected. Effort should be made to curb the immune response by prospective cross-matching, immunosuppressive therapy and preoperative manipulation of homografts to reduce their antigenicity.